Literature DB >> 24565073

Clinical outcomes of endoscopic submucosal dissection for superficial Barrett's adenocarcinoma.

Kenichi Kagemoto1, Shiro Oka2, Shinji Tanaka2, Tomohiro Miwata1, Yuji Urabe1, Yoji Sanomura2, Shigeto Yoshida1, Toru Hiyama3, Koji Arihiro4, Kazuaki Chayama1.   

Abstract

BACKGROUND: Advances in diagnostic techniques have allowed early stage detection of superficial Barrett's adenocarcinoma (SBA) as well as resection by endoscopic submucosal dissection (ESD). Few reports exist, however, on the safety and efficacy of ESD for SBA.
OBJECTIVE: To analyze outcomes of ESD for SBA in relation to clinicopathological features of the lesions.
DESIGN: Retrospective study.
SETTING: University hospital. PATIENTS: Twenty-three patients (21 men, 2 women; mean age, 63 years) with 26 SBAs. INTERVENTION ESD MAIN OUTCOME MEASUREMENTS: We examined outcomes of ESD in relation to the clinicopathological features of SBAs. The main outcomes assessed were en bloc resection rate, operation time, adverse event rates, additional resection rate, and time between ESD and any recurrence.
RESULTS: Twenty lesions (87%) derived from short-segment Barrett's esophagus, and 3 lesions (13%) derived from long-segment Barrett's esophagus. The majority of SBAs (54%) were located in the 0 to 3 o'clock circumferential quadrant. Median tumor size was 15 mm (range 5-60 mm). Macroscopic types were flat elevated (n = 13, 50%), depressed (n = 12, 46%), and protruded (n = 1, 4%). The SBAs appeared red (n = 23, 88%) or normally pale (n = 3, 12%). Under magnifying narrow-band imaging, all SBAs showed an irregular mucosal pattern and an irregular vascular pattern. The endoscopic en bloc resection rate was 100% (26/26), and the pathological en bloc resection rate was 85% (22/26). The median procedure time was 95 minutes (range, 30-210 minutes). Delayed bleeding occurred in 1 case, but there was no perforation. The SBAs were of the differentiated type (n = 25, 96%) or poorly differentiated type (n = 1, 4%). The tumor had invaded the superficial muscularis mucosa (n = 3, 12%), lamina propria mucosa (n = 5, 19%, deep muscularis mucosa (n = 9, 34%), SM1 (n = 3, 12%), and SM2 (n = 6, 23%). Additional surgical resection after ESD was performed in 9 cases, and there were no residual tumors, but 1 lymph node metastasis was found. There were no recurrent tumors; however, 1 metachronous adenocarcinoma was diagnosed 42 months after ESD. LIMITATIONS: Single-center, retrospective study.
CONCLUSIONS: ESD appears to be a safe and effective treatment strategy for early stage SBA.
Copyright © 2014 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24565073     DOI: 10.1016/j.gie.2014.01.022

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  18 in total

Review 1.  Endoluminal therapies for Barrett's esophagus.

Authors:  Carmen L Mueller; Lorenzo E Ferri
Journal:  Obes Surg       Date:  2016-04       Impact factor: 4.129

2.  Postoperative bleeding after gastric endoscopic submucosal dissection in patients receiving antithrombotic therapy.

Authors:  Tsukasa Furuhata; Mitsuru Kaise; Shu Hoteya; Toshiro Iizuka; Akihiro Yamada; Kosuke Nomura; Yasutaka Kuribayashi; Daisuke Kikuchi; Akira Matsui; Osamu Ogawa; Satoshi Yamashta; Toshifumi Mitani
Journal:  Gastric Cancer       Date:  2016-01-11       Impact factor: 7.370

Review 3.  Quality in upper gastrointestinal endoscopic submucosal dissection.

Authors:  Flaminia Purchiaroni; Guido Costamagna; Cesare Hassan
Journal:  Ann Transl Med       Date:  2018-07

4.  Endoscopic submucosal dissection for early Barrett's neoplasia.

Authors:  Maximilien Barret; Dalhia Thao Cao; Frédéric Beuvon; Sarah Leblanc; Benoit Terris; Marine Camus; Romain Coriat; Stanislas Chaussade; Frédéric Prat
Journal:  United European Gastroenterol J       Date:  2015-09-24       Impact factor: 4.623

5.  Endotherapy in case of relapse of neoplastic Barrett's esophagus after successful initial endoscopic resection.

Authors:  Sébastien Godat; Fabrice Caillol; Aurélie Autret; Erwan Bories; Christian Pesenti; Jean Philippe Ratone; Chiara De Cassan; Flora Poizat; Marc Giovannini
Journal:  Surg Endosc       Date:  2017-01-11       Impact factor: 4.584

Review 6.  Expanding Role of Third Space Endoscopy in the Management of Esophageal Diseases.

Authors:  Dennis Yang; Peter V Draganov
Journal:  Curr Treat Options Gastroenterol       Date:  2018-03

Review 7.  Management of Early-Stage Adenocarcinoma of the Esophagus: Endoscopic Mucosal Resection and Endoscopic Submucosal Dissection.

Authors:  Stefan Seewald; Tiing Leong Ang; Roos E Pouw; Fridolin Bannwart; Jacques J Bergman
Journal:  Dig Dis Sci       Date:  2018-08       Impact factor: 3.199

Review 8.  Advances in the management of Barrett's esophagus and early esophageal adenocarcinoma.

Authors:  Ajaypal Singh; Amitabh Chak
Journal:  Gastroenterol Rep (Oxf)       Date:  2015-10-19

9.  Prospective evaluation of the clinical utility of endoscopic submucosal dissection (ESD) in patients with Barrett's esophagus: a Western center experience.

Authors:  Roxana M Coman; Takuji Gotoda; Christopher E Forsmark; Peter V Draganov
Journal:  Endosc Int Open       Date:  2016-03-30

10.  Association of Visceral Fat Area, Smoking, and Alcohol Consumption with Reflux Esophagitis and Barrett's Esophagus in Japan.

Authors:  Juntaro Matsuzaki; Hidekazu Suzuki; Masao Kobayakawa; John M Inadomi; Michiyo Takayama; Kanako Makino; Yasushi Iwao; Yoshinori Sugino; Takanori Kanai
Journal:  PLoS One       Date:  2015-07-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.